Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Spain / NCT06420310
Recruiting Observational

Pesticides and Parkinson´s Disease

NCT06420310 · tracked via the Priya Life Science Spain tracker
Sponsor
Hospital Universitario de Burgos
Phase
Observational
Started
2024-04-01
Last updated
2024-05-20

Condition(s) studied

Pesticide-Induced Parkinsonism

Investigational drug(s) / intervention(s)

exposure to pesticides

exposure to pesticides: based on work exposures to pesticides

Study summary

The aim of this project is to study whether people exposed to pesticides have a higher risk of developing PD. We will perform an epidemiological study determining the presence of pesticides in urine and comparing signs traditionally associated with PD in early forms.

Eligibility

Sex
ALL
Min age
45 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Farmers exposed to pesticides for cases * No work exposure to pesticides for controls Exclusion Criteria: * Subjects without signed consent form * Neurological significant conditions

Primary outcome measure(s)

  • Prodromal PD — over the last year
    Early non motor symptoms

Trial sites (1)

FacilityCityRegionStatus
Hospital Universitario de Burgos Burgos Spain Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06420310 on ClinicalTrials.gov ↗ ← All trials in Spain